DSS, Inc. (NYSE American: DSS), a multinational company operating
businesses within nine divisions and strategically acquiring and
developing assets to enrich the value of its shareholders through
calculated IPO spinoffs and a parametric share distribution
strategy, today announced that less than a year after successfully
synthesizing its first Quantum-based compound, Impact Biomedical,
Inc. and its research partner Global Research and Discovery Group
Sciences (GRDG) developed a Quantum antihistamine that could shift
how medicine is administered while moving the pharmaceutical
industry away from an impending patent cliff.
“What this represents in the bio-chemical field is significant,”
said Daryl Thompson Director of Scientific Initiatives at Global
Research and Discovery Group. “It not only revolutionizes the level
of care we can bring to the patients — which is the most important
part of this project — it also has an impact on the business of
production and dissemination of this technology.”
The Quantum ProjectThe Quantum Antihistamine is
the latest breakthrough in GRDG’s Quantum Project, and has been
successful produced.
The basis of Quantum technology is to enhance the effectiveness
of existing therapeutics by looking beyond current molecular
enhancement techniques such as molecular substitution,
halogenation, prenylation and other biological enhancement methods.
This marriage of quantum and molecular mechanics theoretically
increases the efficacy against a variety of diseases, due in part
to alterations in the intermolecular state. These alterations yield
a molecule with increased molecule-to-ligand interactions with
significantly lower degradation rates. In short, the Quantum
molecule will possess both hyper-reactivity as well as
hyper-persistence.
According to Thompson, this newly-developed quantum
antihistamine compound could be 50 times more effective than
current therapeutics. It would be most effective in fighting
against threats like COVID and other airborne illnesses.
“Vaccines are becoming less effective against newer strains, but
this compound is designed to attack differently,” he said. “It
isn’t the flu virus that does the most harm, it’s the body’s
inflammatory response to the viral infection that kills.”
The quantum antihistamine is revolutionary in three distinct
ways, according to Thompson:
- Because of the significantly increased efficacy, lower doses
are needed and still do more than current therapeutics.
- This less-is-more approach significantly reduces the toxicity
exposure to the body.
- The reduced toxicity can mean that the compound is able to
provide its beneficial effect for a longer period of time thereby
increasing the compound’s overall effectiveness.
“This breakthrough represents a shift in how we create medicines
now and into the future,” said GRDG Chief Scientific Advisor Dr.
Roscoe M. Moore, Jr., the retired United States Assistant Surgeon
General and former Epidemic Intelligence Services (EIS) Officer at
the U.S. Centers for Disease Control. “It is a fundamental move
that will help provide better care to those in need and to combat a
limitless number of ailments that are affecting millions of people
around the world.”
Moore and Thompson see this breakthrough as more than just the
solution to current health issues, but as a paradigm shift on who,
how, and why medicines are created in the first place.
“We’re trying to do something bigger with this resource,” said
Thompson. “We’re seeking to use this technology to rebuild the
pharmaceutical aspect of major continents such as South America and
Africa.”
Over the years, said Thompson, billions of pharmaceutical assets
have been exploited in various parts of the world with very little
return to the home countries. This is especially true notably in
the Amazon region of South America and the Congo in Africa, he
said.
“We are seeking to use quantum to build partnerships with both
of these countries in an effort not only to improve the quality of
life, but to re-establish the pharmacological wealth that has been
lost over the years,” said Thompson.
The Patent CliffPart of the paradigm shift is
aimed at tackling the looming patent cliff. A patent cliff occurs
when the patent expires and a company loses exclusivity on a
product or a group of products that represent a high percentage of
the total market. The drop in sales and the decrease in a company’s
annual revenue impacts that company’s ability to continue research
and development for future patents.
According to reports, investors are growing wary about the
period from 2025-2030, when many big brands will lose market
exclusivity in the United States and Europe and face generic or
biosimilar competition for the first time. Industry watchers
forecast that from 2022-2030, the industry's top drug companies
will lose more than $200 billion.
The top 10 pharmaceutical manufacturers combined have more than
46 percent of their revenues at risk during that time frame, and
five companies have more than 50 percent of their revenues at risk,
according to ZS Associates.
According to the World Health Organization, since 2013 about 95
percent of the world’s essential medicines are off-patent, meaning
that the other 5 percent represents patented medicines, whose
income is supporting further pharmaceutical research and
development.
As that 5 percent move out of patent and into the marketplace
for generic alternatives, there could be an additional $100 billion
impact on the whole industry, which will shrink a company’s ability
to produce new medicines and therapies, stunting the growth of the
industry and affecting the ability of the healthcare industry to
keep the population safe.
Frank D. Heuszel, President of Impact Biomedical, Inc.
astutely observed that the Quantum Project opens a
new landscape for the industry to create and utilize new methods of
research and development that could benefit the whole world.
“Today’s announcement could turn the patent cliff into a virtual
runway of development that could invigorate the pharmaceutical
world,” he said. “The only limit would be the imagination and
determination to create methodologies that incorporate natural
compounds with advanced medicinal chemistry.”
Through the Quantum research project, Impact Biomedical and GRDG
have taken the first step in creating a new way to make medicine.
By boosting the effectiveness of natural compounds with existing
drugs and maintaining the safety profile of the original molecules
Quantum works on a sub-molecular level to increase efficacy.
According to our projections, Quantum could be used to improve and
re-patent up to 65 percent of the World Health Organization’s
Essential Medicines List. If that is the case, it is estimated that
there would be a $200 billion impact to the pharmaceutical
industry.
About Impact BioMedical, Inc.Impact BioMedical,
Inc. ("Impact BioMedical") is a wholly owned subsidiary of DSS.
Impact BioMedical strives to leverage its scientific know-how and
intellectual property rights to provide solutions that have been
plaguing the biomedical field for decades. By tapping into the
scientific expertise of GRDG Sciences, LLC, Impact BioMedical
pledges to undertake a concerted effort in the R&D, drug
discovery and development for the prevention, inhibition, and
treatment of neurological, oncological and immuno -related
diseases. For more information on Impact BioMedical
visit http://impbio.com/.
About DSS, Inc.DSS is a multinational company
operating businesses within nine divisions: Product Packaging,
Biotechnology, Direct Marketing, Commercial Lending, Securities and
Investment Management, Alternative Trading, Digital Transformation,
Secure Living, and Alternative Energy. DSS strategically acquires
and develops assets to enrich the value of its shareholders through
calculated IPO spinoffs and a parametric share distribution
strategy. Since 2019, under the guidance of new leadership, DSS has
built the necessary foundation for achievable growth through the
formation of a diversified portfolio of companies positioned to
drive profitability in multiple high growth sectors. These
companies offer innovative, flexible, and real-world solutions that
not only provide mutual benefits for businesses and their
customers, but also create sustainable value and opportunity for
transformation.
For more information on DSS
visit http://www.dssworld.com.
Investor Contact:Dave Gentry, CEORedChip Companies
Inc.407-491-4498DSS@redchip.com
Safe Harbor DisclosureThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Such forward-looking
statements include, but are not limited to, statements related to
the Company's intended use of proceeds and other statements that
are not historical facts. Forward-looking statements are based on
management's current expectations and are subject to risks and
uncertainties that may cause actual results or events to differ
materially from those projected. These risks and uncertainties,
many of which are beyond our control, include: risks relating to
our growth strategy; our ability to obtain, perform under and
maintain financing and strategic agreements and relationships;
risks relating to the results of development activities; our
ability to attract, integrate and retain key personnel; our need
for substantial additional funds; patent and intellectual property
matters; competition; as well as other risks described in our SEC
filings, including, without limitation, our reports on Forms 8-K,
10-K and 10-Q, all of which can be obtained on the SEC website at
www.sec.gov. Readers are cautioned not to place undue reliance on
the forward-looking statements, which speak only as of the date on
which they are made and reflect management's current estimates,
projections, expectations, and beliefs. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions, or circumstances on which any such statement is based,
except as required by law.
DSS (AMEX:DSS)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
DSS (AMEX:DSS)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024